Research
Hormonal
Multi-receptor agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single-target GLP-1RAs by simultaneously activating multiple gut hormone receptors (GLP-1R, GIPR, GCGR).
Newer 'multi-agonist' drugs like Tirzepatide and Retatrutide are even more effective for weight loss than older GLP-1 drugs, achieving up to 24% body weight loss in trials. They work by targeting multiple hormone receptors. They are taken once weekly. They are prescription medications and can cause gastrointestinal side effects.
StrongSupportsVERY_HIGH confidence
Tirzepatide是一种单分子多肽，可同时激动GIPR和GLP-1RA... Retatrutide是一种GIP/GLP-1/GCG三受体激动剂... 第48周时，12 mg组平均体重减轻可达24.2%
Why this rating
Based on phase 2/3 clinical trials (SURMOUNT-1, Retatrutide phase 2).
Source
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Jun Yin et al. · Chinese Science Bulletin (Chinese Version) · 2024
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →